Therapeutic prospects of mesenchymal stem/stromal cells in COVID-19 associated pulmonary diseases: From bench to bedside

doi:10.4252/wjsc.v13.i8.1058

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4879)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

298

WORD

135

HTML

2741

Figures (1-3)

338

Sum=3512

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

325

Download

1042

Sum=1367

Aug 26, 2021 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Aug 26, 2021; 13(8): 1058-1071
Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.1058

Full Size Figure Download Figure

Figure 3 Detailed information of mesenchymal stem/stromal cell-based cytotherapy for coronavirus disease 2019. A: Distribution of registered clinical trials among the countries for coronavirus disease 2019 (COVID-19) treatment by utilizing mesenchymal stem/stromal cell (MSC)-based cytotherapy; B: Study phase of registered clinical trials; C: Distribution of subtypes of applied MSCs for COVID-19 treatment; D: Distribution of symptoms in patients with COVID-19 before MSC-based cytotherapy. MSCs: Mesenchymal stem/stromal cells; COVID-19: Coronavirus disease 2019.

Citation: Zhang LS, Yu Y, Yu H, Han ZC. Therapeutic prospects of mesenchymal stem/stromal cells in COVID-19 associated pulmonary diseases: From bench to bedside. World J Stem Cells 2021; 13(8): 1058-1071
URL: https://www.wjgnet.com/1948-0210/full/v13/i8/1058.htm
DOI: https://dx.doi.org/10.4252/wjsc.v13.i8.1058